Elicio Therapeutics Inc.

Contributing Author

Recent Articles by Elicio Therapeutics Inc.

Nov-05	Elicio Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update ELTX -10.26% ELTX +7.86% GlobeNewswire
Nov-04	Elicio Therapeutics to Host Virtual KOL Event on November 11, 2026: ELI-002 7P for Metastatic and Neoadjuvant PDAC ELTX GlobeNewswire
Oct-29	Elicio Therapeutics to Present Phase 2 AMPLIFY-7P Results at the SITC 2026 Annual Meeting ELTX -5.41% GlobeNewswire
Oct-23	Elicio Therapeutics Presents Late-Breaking Phase 2 AMPLIFY-7P Results at ESMO Congress 2026 and Announces Simultaneous Publication in Nature Medicine ELTX GlobeNewswire
Sep-24	Elicio Therapeutics Announces Late-Breaking Phase 2 AMPLIFY-7P Data Selected for Proffered Paper Oral Presentation at ESMO Congress 2026 ELTX GlobeNewswire
Aug-31	Elicio Therapeutics to Participate at the H.C. Wainwright 28th Annual Global Investment Conference ELTX GlobeNewswire
Aug-24	Elicio Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference ELTX GlobeNewswire
Aug-13	Elicio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Updates ELTX GlobeNewswire
Aug-10	Elicio Therapeutics Announces Activation of the Investigator-Initiated Phase 1 Study of Neoadjuvant ELI-002 7P for Pancreatic Ductal Adenocarcinoma ELTX GlobeNewswire
Jul-06	Elicio Therapeutics Announces Closing of $15 Million Registered Direct Offering ELTX ELTX -15.02% GlobeNewswire
Jul-02	Elicio Therapeutics Announces Pricing of $15 Million Registered Direct Offering ELTX -37.35% GlobeNewswire
Jun-29	Elicio Therapeutics Added to Russell 2000 and Russell 3000 Indexes ELTX GlobeNewswire
Jun-17	Elicio Therapeutics Reports Multiple Complete Responses After ELI-002 7P Treatment and Subsequent Therapy with Checkpoint Inhibition in Metastatic mKRAS Pancreatic Cancer ELTX +70.65% GlobeNewswire
Jun-15	Elicio Therapeutics Reports Results from Phase 2 AMPLIFY-7P Study and Outlines Refined Phase 3 Development Strategy for ELI-002 7P in Adjuvant Pancreatic Cancer ELTX -72.53% GlobeNewswire
Jun-01	Elicio Therapeutics Announces Publication in Peer-Reviewed Journal Science Advances Highlighting Potent and Durable Immune Responses Driven by Company's AMP-DNA Adjuvant Technology ELTX +5.94% GlobeNewswire
May-11	Elicio Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Updates ELTX +17.15% ELTX -9.13% GlobeNewswire
Apr-30	Elicio Therapeutics to Present at the Bank of America Healthcare Conference ELTX GlobeNewswire
Apr-16	Elicio Therapeutics Reports Inducement Grants ELTX +6.96% GlobeNewswire
Mar-17	Elicio Therapeutics Reports Inducement Grants ELTX GlobeNewswire
Mar-12	Elicio Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Updates ELTX -7.55% ELTX +11.93% GlobeNewswire
Feb-25	Elicio Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference ELTX +10.35% GlobeNewswire
Feb-18	Elicio Therapeutics Reports Inducement Grants ELTX GlobeNewswire
Jan-16	Elicio Therapeutics Reports Inducement Grants ELTX +5.63% GlobeNewswire
Dec-16	Elicio Therapeutics Reports Inducement Grants ELTX GlobeNewswire
Dec-11	Elicio Therapeutics Reports Antigen Spreading to Patient-Specific Neoantigens Beyond mKRAS in Ongoing Phase 2 AMPLIFY-7P Trial ELTX GlobeNewswire
Nov-19	Elicio Therapeutics Appoints Veteran CMC and Technical Operations Executive Marc J. Wolfgang as Chief Technology Officer ELTX -5.48% GlobeNewswire
Nov-13	Elicio Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Updates ELTX GlobeNewswire
Nov-07	Elicio Therapeutics Reports Robust, Cytolytic mKRAS-Specific T Cell Responses Across Diverse Patient HLA in Ongoing Phase 2 AMPLIFY-7P Trial of ELI-002 7P and New ELI-004 Preclinical Data at SITC ELTX GlobeNewswire
Nov-03	Elicio Therapeutics to Present Clinical and Preclinical Data at the SITC 2025 Annual Meeting ELTX GlobeNewswire
Oct-27	Elicio Therapeutics Reports Robust T cell Responses Across Diverse HLA backgrounds in Ongoing Phase 2 AMPLIFY-7P Trial ELTX GlobeNewswire
Sep-29	Elicio Therapeutics Announces Investigator-Initiated Phase 1 Trial to be Conducted by Memorial Sloan Kettering Cancer Center and funded by The Lustgarten Foundation for Neoadjuvant ELI-002 7P in Pancreatic Ductal Adenocarcinoma ELTX GlobeNewswire
Sep-18	Elicio Therapeutics Reports Inducement Grants ELTX GlobeNewswire
Sep-17	Elicio Therapeutics Reports ELI-002 7P Achieved Robust mKRAS-Specific T Cell Responses in 99% of Evaluable Patients in Ongoing Phase 2 AMPLIFY-7P Trial ELTX GlobeNewswire
Aug-12	Elicio Therapeutics Announces Publication of ELI-002 Updated AMPLIFY-201 Phase 1 Follow-up Data in Nature Medicine for Minimal Residual Disease ("MRD") Positive, Adjuvant-Stage Patients ELTX +8.67% GlobeNewswire
Aug-07	Elicio Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Updates ELTX GlobeNewswire
Aug-05	Elicio Therapeutics Announces Positive Recommendation by IDMC to Continue ELI-002 7P Randomized Phase 2 Study in Pancreatic Cancer Without Modifications to Final Analysis ELTX -7.96% GlobeNewswire
Jun-17	Elicio Therapeutics to Host Virtual KOL Event on June 25, 2025 to Discuss AMP-Powered ELI-002 for the Treatment of KRAS mutation-driven Pancreatic Cancer ELTX GlobeNewswire
Jun-04	Elicio Therapeutics Secures $10 Million in Financing ELTX GlobeNewswire
May-13	Elicio Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Updates ELTX ELTX -5.25% GlobeNewswire

Elicio Therapeutics Inc.

Recent Articles by Elicio Therapeutics Inc.

Upgrade your Finviz experience